SE0100569D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE0100569D0
SE0100569D0 SE0100569A SE0100569A SE0100569D0 SE 0100569 D0 SE0100569 D0 SE 0100569D0 SE 0100569 A SE0100569 A SE 0100569A SE 0100569 A SE0100569 A SE 0100569A SE 0100569 D0 SE0100569 D0 SE 0100569D0
Authority
SE
Sweden
Prior art keywords
new compounds
active compounds
preparation
compounds
new
Prior art date
Application number
SE0100569A
Other languages
English (en)
Swedish (sv)
Inventor
Stefan Berg
Sven Hellberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0100569A priority Critical patent/SE0100569D0/xx
Publication of SE0100569D0 publication Critical patent/SE0100569D0/xx
Priority to BR0206935-0A priority patent/BR0206935A/pt
Priority to US10/468,604 priority patent/US7345050B2/en
Priority to PL02363393A priority patent/PL363393A1/pl
Priority to PCT/SE2002/000271 priority patent/WO2002065979A2/en
Priority to EP02711620A priority patent/EP1373266A2/en
Priority to KR10-2003-7010874A priority patent/KR20030084935A/ko
Priority to CA002434648A priority patent/CA2434648A1/en
Priority to NZ526783A priority patent/NZ526783A/en
Priority to JP2002565540A priority patent/JP4475869B2/ja
Priority to CZ20032235A priority patent/CZ20032235A3/cs
Priority to IL15678102A priority patent/IL156781A0/xx
Priority to MXPA03007320A priority patent/MXPA03007320A/es
Priority to CNB028052471A priority patent/CN1294131C/zh
Priority to HK05102865.3A priority patent/HK1070071B/xx
Priority to SK1025-2003A priority patent/SK10252003A3/sk
Priority to HU0303254A priority patent/HUP0303254A2/hu
Priority to RU2003121307/04A priority patent/RU2003121307A/ru
Priority to EEP200300400A priority patent/EE200300400A/xx
Priority to IS6868A priority patent/IS6868A/is
Priority to BG108070A priority patent/BG108070A/bg
Priority to ZA200306171A priority patent/ZA200306171B/xx
Priority to NO20033679A priority patent/NO20033679L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0100569A 2001-02-20 2001-02-20 New compounds SE0100569D0 (sv)

Priority Applications (23)

Application Number Priority Date Filing Date Title
SE0100569A SE0100569D0 (sv) 2001-02-20 2001-02-20 New compounds
EEP200300400A EE200300400A (et) 2001-02-20 2002-02-18 Pürimidiiniühendid, nende valmistamismeetod ning kasutamine
CZ20032235A CZ20032235A3 (cs) 2001-02-20 2002-02-18 Nové pyrimidinové sloučeniny
MXPA03007320A MXPA03007320A (es) 2001-02-20 2002-02-18 Nuevos compuestos de pirimidina.
PL02363393A PL363393A1 (pl) 2001-02-20 2002-02-18 Nowe związki pirymidynowe
PCT/SE2002/000271 WO2002065979A2 (en) 2001-02-20 2002-02-18 (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes
EP02711620A EP1373266A2 (en) 2001-02-20 2002-02-18 (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes
KR10-2003-7010874A KR20030084935A (ko) 2001-02-20 2002-02-18 Ｃｎｓ 장애 및 당뇨병의 치료에 사용하기 위한(디아졸로-피리디닐)-피리미딘
CA002434648A CA2434648A1 (en) 2001-02-20 2002-02-18 (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes
NZ526783A NZ526783A (en) 2001-02-20 2002-02-18 (Diazolo-pyridinyl)-pyrimidines for use in treatment of CNS disorders and diabetes
JP2002565540A JP4475869B2 (ja) 2001-02-20 2002-02-18 新規なピリミジン化合物
BR0206935-0A BR0206935A (pt) 2001-02-20 2002-02-18 Composto, formulação farmacêutica, uso de um composto, método de tratamento e/ou profilaxia de condições associadas com a inibição da glicogênio sintase quinase-3, e, processo para a preparação de um composto
IL15678102A IL156781A0 (en) 2001-02-20 2002-02-18 (diazolo-pyridinyl)-pyrimidines for use in teatment of cns disorders and diabetes
US10/468,604 US7345050B2 (en) 2001-02-20 2002-02-18 Pyrimidine compounds
CNB028052471A CN1294131C (zh) 2001-02-20 2002-02-18 新嘧啶化合物
HK05102865.3A HK1070071B (en) 2001-02-20 2002-02-18 New pyrimidine compounds
SK1025-2003A SK10252003A3 (sk) 2001-02-20 2002-02-18 Pyrimidínové zlúčeniny
HU0303254A HUP0303254A2 (hu) 2001-02-20 2002-02-18 Új pirimidinvegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
RU2003121307/04A RU2003121307A (ru) 2001-02-20 2002-02-18 (диазоло-пиридинил)-пиримидины для применения в лечении нарушений центральной нервной системы и диабета
IS6868A IS6868A (is) 2001-02-20 2003-07-08 Ný pýrimidínefnasambönd
BG108070A BG108070A (bg) 2001-02-20 2003-08-07 Нови пиримидинови съединения
ZA200306171A ZA200306171B (en) 2001-02-20 2003-08-08 (Diazolo-pyridinyl)-pyrimidines for use in treatment of CNS disorders and diabetes.
NO20033679A NO20033679L (no) 2001-02-20 2003-08-19 Nye pyrimidinforbindelser

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0100569A SE0100569D0 (sv) 2001-02-20 2001-02-20 New compounds

Publications (1)

Publication Number Publication Date
SE0100569D0 true SE0100569D0 (sv) 2001-02-20

Family

ID=20283059

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0100569A SE0100569D0 (sv) 2001-02-20 2001-02-20 New compounds

Country Status (22)

Country Link
US (1) US7345050B2 (pl)
EP (1) EP1373266A2 (pl)
JP (1) JP4475869B2 (pl)
KR (1) KR20030084935A (pl)
CN (1) CN1294131C (pl)
BG (1) BG108070A (pl)
BR (1) BR0206935A (pl)
CA (1) CA2434648A1 (pl)
CZ (1) CZ20032235A3 (pl)
EE (1) EE200300400A (pl)
HU (1) HUP0303254A2 (pl)
IL (1) IL156781A0 (pl)
IS (1) IS6868A (pl)
MX (1) MXPA03007320A (pl)
NO (1) NO20033679L (pl)
NZ (1) NZ526783A (pl)
PL (1) PL363393A1 (pl)
RU (1) RU2003121307A (pl)
SE (1) SE0100569D0 (pl)
SK (1) SK10252003A3 (pl)
WO (1) WO2002065979A2 (pl)
ZA (1) ZA200306171B (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2003076434A1 (en) 2002-03-09 2003-09-18 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0226583D0 (en) * 2002-11-14 2002-12-18 Cyclacel Ltd Compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
US20080207594A1 (en) 2005-05-04 2008-08-28 Davelogen Aktiengesellschaft Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
UY29827A1 (es) * 2005-10-03 2007-05-31 Astrazeneca Ab 2-amina-pirimidina-4-(2-metil-1-(tetrahidro-2h-piran-4-il)-1-imidazol-5-y1) sustituidas y sus derivados, composiciones farmacéuticas que las contienen, procesos para su preparación y aplicaciones
EP1942897A1 (en) * 2005-10-03 2008-07-16 AstraZeneca AB Use of pyrimidine derivatives in the manufacture of a medicament for prevention and/or treatment of alzheimer's disease
DE602006021645D1 (de) 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
EP2121613A2 (en) * 2007-01-31 2009-11-25 Vertex Pharmaceuticals, Inc. 2-aminopyridine derivatives useful as kinase inhibitors
TWI468417B (zh) 2007-11-30 2015-01-11 Genentech Inc 抗－ｖｅｇｆ抗體
ES2524259T3 (es) * 2008-03-24 2014-12-04 Novartis Ag Inhibidores de metaloproteinasa de matriz a base de arilsulfonamida
JP5640005B2 (ja) 2008-07-14 2014-12-10 ギリアード サイエンシーズ， インコーポレイテッド Ｈｄａｃおよび／またはｃｄｋ阻害剤としてのイミダゾシルピリジン化合物
EP2303881A2 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Fused heterocyclyc inhibitors of histone deacetylase and/or cyclin-dependent kinases
EP2303841A1 (en) 2008-07-14 2011-04-06 Gilead Sciences, Inc. Oxindolyl inhibitor compounds
KR20110038159A (ko) 2008-07-28 2011-04-13 길리애드 사이언시즈, 인코포레이티드 사이클로알킬리덴 및 헤테로사이클로알킬리덴 히스톤 데아세틸라아제 억제제 화합물
CA2741089A1 (en) 2008-10-22 2010-04-29 Genentech, Inc. Modulation of axon degeneration
EP2419425A4 (en) 2009-04-15 2012-08-29 Astrazeneca Ab IMIDAZOLE SUBSTITUTED PYRIMIDINES USEFUL IN THE TREATMENT OF GLYCOGEN SYNTHASE KINASE 3 RELATED DISORDERS, SUCH AS ALZHEIMER'S DISEASE
ES2463826T3 (es) 2009-06-08 2014-05-29 Gilead Sciences, Inc. Compuestos inhibidores de HDAC de cicloalquilcarbamato benzamida anilina
CA2763786C (en) 2009-06-08 2014-09-30 Gilead Sciences, Inc. Alkanoylamino benzamide aniline hdac inihibitor compounds
KR102414221B1 (ko) 2020-08-04 2022-06-27 서울시립대학교 산학협력단 열전 소자 어셈블리, 이의 제조 방법, 및 이를 포함하는 열전 모듈

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE29032E (en) * 1969-06-12 1976-11-09 Riker Laboratories, Inc. 3-Benzoylfluoro-methanesulfonanilides
FR2179493A1 (en) * 1972-04-10 1973-11-23 Roussel Uclaf Amino benzhydrols - choleretics anticonvulsants sedatives and barbiturate potentiators
DE3042466A1 (de) * 1980-11-11 1982-06-16 A. Nattermann & Cie GmbH, 5000 Köln N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (pl) * 1992-04-03 1994-06-21 Ciba Geigy Ag
GB9523675D0 (en) * 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9701453D0 (en) * 1997-01-24 1997-03-12 Leo Pharm Prod Ltd Aminobenzophenones
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds

Also Published As

Publication number Publication date
BG108070A (bg) 2004-07-30
JP4475869B2 (ja) 2010-06-09
PL363393A1 (pl) 2004-11-15
EE200300400A (et) 2003-12-15
US7345050B2 (en) 2008-03-18
CA2434648A1 (en) 2002-08-29
CN1294131C (zh) 2007-01-10
NO20033679D0 (no) 2003-08-19
EP1373266A2 (en) 2004-01-02
HUP0303254A2 (hu) 2004-01-28
CZ20032235A3 (cs) 2004-01-14
WO2002065979A2 (en) 2002-08-29
JP2004527486A (ja) 2004-09-09
HK1070071A1 (en) 2005-06-10
MXPA03007320A (es) 2003-12-04
SK10252003A3 (sk) 2004-02-03
US20040077642A1 (en) 2004-04-22
KR20030084935A (ko) 2003-11-01
NO20033679L (no) 2003-08-19
IS6868A (is) 2003-07-08
BR0206935A (pt) 2004-06-29
WO2002065979A3 (en) 2003-02-20
NZ526783A (en) 2005-04-29
RU2003121307A (ru) 2005-02-27
CN1537112A (zh) 2004-10-13
IL156781A0 (en) 2004-02-08
ZA200306171B (en) 2004-11-08

Similar Documents

Publication Publication Date Title
SE0200979D0 (sv) New compounds
TW200745111A (en) New compounds
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
TW200510375A (en) New compounds
UY27368A1 (es) Nuevos compuestos
SE0102439D0 (sv) New compounds
ATE365720T1 (de) Agonisten von beta-adrenorezeptoren
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
BR0211473A (pt) Novos compostos
EA200300776A1 (ru) Производные фенэтаноламина для лечения респираторных заболеваний
MXPA02007942A (es) Derivados de pirrolopirimidinona, procesos de preparacion y uso.
GB0003154D0 (en) Novel compounds
BR0211472A (pt) Novos compostos
NO20024005D0 (no) Pteridinforbindelser for behandling av psoriasis
IS6520A (is) Ný efnasambönd
SE9904508D0 (sv) New compounds
WO2002065979A3 (en) (diazolo-pyridinyl)-pyrimidines for use in treatment of cns disorders and diabetes
SE0102440D0 (sv) New compound
SE0102055D0 (sv) New Compounds
SE0104331D0 (sv) Novel compounds
SE0101322D0 (sv) Novel compounds
SE0401655D0 (sv) New compounds
ATE253359T1 (de) Antithrombotische mittel
SE0102057D0 (sv) New Salts I
IT1307786B1 (it) Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.